Our results provide further support for the dual role of HMGB1 in the pathophysiology of myocardial infarction and highlight its potential as a therapeutic target not only for reducing inflammation and oxidative stress, but also for limiting adverse fibrotic remodeling of the myocardium. This evidence concerns the gene HMGB1 and myocardial infarction.